Patent intelligence · US
US 10307481
CD37 immunotherapeutics and uses thereof
CD37 immunotherapeutics and uses thereof
Patent details — US 10307481
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 4, 2019
- Expiration
- May 30, 2039
- Applicant
- Aptevo Research and Development LLC
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/545
Quick answer
US 10307481 (CD37 immunotherapeutics and uses thereof) is held by Aptevo Research and Development LLC. Status: granted. Granted Jun 4, 2019. Expires May 30, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aptevo Research and Development LLC
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K39/3955, A61K39/39558
More from Aptevo Research and Development LLC
Related pharmaceutical patents in our USPTO index.
-
US 11939392
CD123 binding proteins and related compositions and methods
granted -
US 11725060
Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
granted -
US 11352426
CD3 binding polypeptides
granted -
US 11312786
Oncofetal antigen binding proteins and related compositions and methods
granted -
US 11242400
CD123 binding proteins and related compositions and methods
granted -
US 10676533
Methods of treatment of CD123 overexpressing disorders
granted -
US 10239949
Oncofetal antigen binding proteins and related compositions and methods
granted
Related coverage
Frequently asked questions
What is US patent 10307481?
US 10307481 (CD37 immunotherapeutics and uses thereof) is held by Aptevo Research and Development LLC. Status: granted. Granted Jun 4, 2019. Expires May 30, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10307481?
Aptevo Research and Development LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does US 10307481 expire?
Our index shows an expiration date of May 30, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.